Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: Report of a case

Surgery Today

Volumn 37, Issue 12, 2007, Pages 1105-1109

  Ludvigsen, Lisbeth ^a   Toxværd, Anders ^a   Mahdi, Bassam ^a   Krarup Hansen, Anders ^a   Bergenfeldt, Magnus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Duodenal neoplasms; Gastrointestinal stromal tumors; Imatinib; Neoadjuvant therapy; Pancreaticoduodenectomy

Indexed keywords

IMATINIB;

ADRENAL GLAND; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; DUODENUM TUMOR; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; KIDNEY SURGERY; MALE; PANCREATICODUODENECTOMY; RECURRENCE RISK;

ADULT; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENAL NEOPLASMS; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATICODUODENECTOMY; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36448995057     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-007-3544-2     Document Type: Article

References (23)

1. MT Mazur HB Clark 1983 Gastric stromal tumors: reappraisal of histogenesis Am J Surg Pathol 7 507 19
2. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 80
3. BP Rubin S Singer C Tsao A Duensing ML Lux R Ruiz 2001 KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 8118 21
4. CD Fletcher JJ Berman C Corless F Gorstein J Lasota BJ Longley 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 65
5. JY Blay S Bonvalot P Casali H Choi M Debiec-Richter AP Dei Tos 2005 Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 566 78
6. LG Kindblom HE Remotti F Aldenborg JM Meis-Kindblom 1998 Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal Am J Pathol 152 1259 69
7. H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 6
8. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 80
9. J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 34
10. BL Eisenberg I Judson 2004 Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol 11 465 75
11. TS Emory LH Sobin L Lukes DH Lee TJ O'Leary 1999 Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site Am J Surg Pathol 23 82 7
12. JK Greenson 2003 Gastrointestinal stromal tumors and other mesenchymal lesions of the gut Mod Pathol 16 366 75
13. RP DeMatteo JJ Lewis D Leung SS Mudan JM Woodruff MF Brennan 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 8
14. EH Ng RE Pollock MF Munsell EN Atkinson MM Romsdahl 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging Ann Surg 215 68 77
15. PC McGrath JP Neifeld W Lawrence Jr S Kay JS Horsley III GA Parker 1987 Gastrointestinal sarcomas: analysis of prognostic factors Ann Surg 206 706 10
16. M Van Glabbeke J Verweij PG Casali A Le Cesne P Hohenberger I Ray-Coquard 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795 804
17. H Choi 2005 Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model Curr Oncol Rep 7 307 11
18. P Bümming J Andersson JM Meis-Kindblom H Klingenstierna K Engstrom U Stierner 2003 Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients Br J Cancer 89 460 4
19. D Katz A Segal Y Alberton O Jurim P Reissman R Catane 2004 Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor Anticancer Drugs 15 599 602
20. CL Scaife KK Hunt SR Patel RS Benjamin MA Burgess LL Chen 2003 Is there a role for surgery in patients with "unresectable" cKIT + gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186 665 9
21. PC Wu A Langerman CW Ryan J Hart S Swiger MC Posner 2003 Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era Surgery 134 656 65
22. JN Shah W Sun RR Seethala VA Livolsi RD Fry GG Ginsberg 2005 Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor Gastrointest Endosc 61 625 7
23. SS Lo GI Papachristou SD Finkelstein WP Conroy WH Schraut RK Ramanathan 2005 Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case Dis Colon Rectum 48 1316 9